Jazz Pharmaceuticals (JAZZ) PT Lowered to $186 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $231.32 +0.69%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 25 | New: 12
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 25 | New: 12
Join SI Premium – FREE
BofA Securities analyst Jason Gerberry lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $186.00 (from $210.00) while maintaining a Buy rating.
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $319 at Morgan Stanley
- Jazz Pharmaceuticals (JAZZ) PT Raised to $310 at JPMorgan
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
